RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets tough lymphoma in early trial
Disease control OngoingThis early-phase study tests a new drug (JNJ-87801493) combined with immune-activating therapies (T-cell engagers) in about 70 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to other treatments. The main goals are to check safety and find the best dos…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control OngoingThis study tests a new drug called englumafusp alfa, which helps the immune system attack cancer cells. It is given together with either obinutuzumab or glofitamab to people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. The trial has three par…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called glofitamab, given alone or with obinutuzumab, in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior treatments. The trial has three parts to find the best dose and check safety and effectiveness. About 940 par…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy hopes to tackle tough lymphoma
Disease control OngoingThis trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 2…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New chemo cocktail aims to make stem cell transplants safer for seniors
Disease control OngoingThis early-phase study tests a combination of three drugs (rituximab, bendamustine, and melphalan) followed by a stem cell transplant using the patient's own cells. The goal is to see if this approach is safe and has fewer side effects than standard treatments for older adults wi…
Matched conditions: RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC